Clopidogrel resistance after renal transplantation

Adam Varga, Barbara Sandor, Karoly Kalmar Nagy, Dora Praksch, Katalin Gombos, Andras Toth, Kalman Toth, Peter Szakaly

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Leading causes of mortality and morbidity after kidney transplantation are cardiovascular diseases. One of the fundamentals of their prevention is the inhibition of platelet aggregation. Resistance to anti-platelet agents is a well-established phenomenon; however, its causes are yet to be clarified. Patients and Methods: Forty post-transplant patients, who received 75 mg clopidogrel q.d. as a prophylactic measure, were examined using optical aggregometry. Subsequently, logistic regression analysis was performed with 24 variables in order to expose possible causes of resistance. Results: Sixty percent of patients (24) were resistant to clopidogrel therapy; effective thrombocyte inhibition could only be shown in 40% of them (16). Significant correspondence between resistance and variables could not be found. Conclusion: Clopidogrel resistance is expected to occur on a large scale in patients who underwent kidney transplant surgery. Thus, a key component of preventive therapy, which stresses the importance of discovering the cause of resistance so as to decrease mortality rates, is missing.

Original languageEnglish
Pages (from-to)301-304
Number of pages4
JournalIn Vivo
Volume29
Issue number2
Publication statusPublished - Mar 1 2015

    Fingerprint

Keywords

  • Cardiovascular complication
  • Clopidogrel resistance
  • Platelet aggregation
  • Transplantation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Cite this

Varga, A., Sandor, B., Nagy, K. K., Praksch, D., Gombos, K., Toth, A., Toth, K., & Szakaly, P. (2015). Clopidogrel resistance after renal transplantation. In Vivo, 29(2), 301-304.